Dianthus Therapeutics, a clinical-stage biotechnology company, has recently released its 10-K report, detailing its operations and financial performance. The company, founded in 2019 and headquartered in New York, is dedicated to developing complement therapeutics for patients with severe autoimmune and inflammatory diseases. Its lead product candidate, claseprubart, is a monoclonal antibody designed for less frequent and more convenient self-administered subcutaneous injections. The company's second clinical-stage candidate, DNTH212, is a bifunctional fusion protein targeting plasmacytoid dendritic cell BDCA2 to reduce Type 1 interferon production and inhibit BAFF/APRIL to suppress B cell function.
In its Management’s Discussion and Analysis of Financial Condition and Results of Operations, Dianthus Therapeutics reported a successful public offering in September 2025, generating gross proceeds of $288.4 million. The company intends to use the net proceeds to advance its preclinical and clinical development activities, as well as for working capital and general corporate purposes. Dianthus Therapeutics also highlighted the impact of global and macroeconomic developments, acknowledging the uncertainty in the global economy and its potential risks to the business.
The company has not generated any revenue from product sales since its inception and does not expect to do so in the foreseeable future. However, it has recognized revenues from upfront payments, milestone payments, and cost reimbursements under its license agreements. Dianthus Therapeutics also disclosed a licensing agreement with Zenas BioPharma, Inc., including various payments and reimbursements related to the development and commercialization of certain sequences and products under an identified antibody sequence.
Dianthus Therapeutics provided an update on its clinical trials, reporting positive top-line results from the Phase 2 MaGic trial of claseprubart for patients with generalized Myasthenia Gravis. The company also announced the achievement of its target of 20 confirmed responders in the CAPTIVATE trial for patients with Chronic Inflammatory Demyelinating Polyneuropathy, and the initiation of the MoMeNtum trial for patients with Multifocal Motor Neuropathy. Additionally, Dianthus Therapeutics entered into an exclusive license agreement for DNTH212, with a Phase 1 study in China initiated in healthy volunteers and patients with systemic lupus erythematosus.
Today the company's shares have moved 0.23% to a price of $44.10. For the full picture, make sure to review Dianthus Therapeutics's 10-K report.
